SGD can significantly change the mRNA expression of genes related to the BAs metabolic pathway, and improve dyslipidemia in PCOS rats by reshaping the gut microbiota structure and regulating the bile acid/FXR pathway. The gene discussed is NR1H4; the disease is polycystic ovary syndrome.